Edwards Lifesciences Shares New Data on Mitral and Tricuspid Therapies
Edwards Lifesciences (NYSE: EW) shared new data demonstrating successful outcomes with its mitral and tricuspid therapies at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
New Findings for Evoque and Sapien M3 Valves
The company presented new findings for its Evoque and Sapien M3 valves, adding to new long-term findings for Sapien valves also shared at TCT.
- One-year data from the ENCIRCLE single-arm pivotal trial
- 30-day data from the EVOQUE STS/ACC TVT registry
ENCIRCLE achieved all primary and secondary endpoints for safety and effectiveness, with data published in The Lancet. EVOQUE outperformed results from the company’s previous TRISCEND II pivotal trial for the tricuspid valve.
No direct quote available in the text.
Author's summary: Edwards Lifesciences shares successful data on mitral and tricuspid therapies.
More News
- F1 2026 : Lancements, livrées et premiers indices d'une révolution en piste
- Hamilton urges Ferrari to make 'personnel changes' ahead of F1 2026
- JUST IN: Kelly Olynyk has been waived by the San Antonio Spurs
- Islanders vs. Lightning (Dec 6, 2025) Pregame
- Jack Osbourne breaks silence on jungle feud with Kelly Brook
- Spurs' Luke Kornet out Friday
- Pelicans' Questionable Offseason Trade Looks Better After Saddiq Bey's Rise
- Game Preview: Islanders vs Lightning
- Kelly Vedovelli révèle sa vie amoureuse
- Tampa Bay Lightning vs. New York Islanders - Game Highlights